Welcome to our dedicated page for Candel Therapeutics SEC filings (Ticker: CADL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Candel Therapeutics, Inc. filings document a clinical-stage oncology company developing multimodal biological immunotherapies and reporting as a Nasdaq-listed issuer of common stock. Its proxy materials cover director elections, auditor ratification and annual-meeting voting matters, while Form 8-K reports furnish operating and financial results and research-and-development presentations.
Other filings disclose material agreements and capital-structure matters, including term-loan financing and facility lease amendments, along with clinical and regulatory disclosures tied to aglatimagene besadenovec and linoserpaturev. The filing record also reflects governance matters, shareholder voting mechanics and exhibit-based disclosures for key corporate actions.
Candel Therapeutics, Inc. (CADL) reported that Chief Executive Officer and director Paul Peter Tak exercised options and sold shares of common stock. On September 10, 2026, he exercised options to acquire 125,000 shares at $1.55 per share, and on the same day sold 220,866 shares at a weighted average price of $11.4997 per share in multiple trades. On September 11, 2026, he sold an additional 59,379 shares at a weighted average price of $10.4564 per share in multiple trades. The option exercise related to an award expiring on October 10, 2030, and following that exercise 1,638,968 option-linked shares remained outstanding. All reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2026 and modified on June 11, 2026.
Candel Therapeutics, Inc. (CADL) received a notice that stockholder Paul Peter Tak intends to sell up to 280,245 shares of common stock under Rule 144 through Morgan Stanley Smith Barney LLC. The filing lists an aggregate market value of $3,410,581.65 for these shares and references 76,518,565 shares outstanding of the same class.
The shares derive from equity compensation: 125,000 shares from stock options to be exercised on September 10, 2026, 12,900 shares from previously exercised options dated November 21, 2024, and 142,345 shares from restricted stock units with an acquisition date of July 9, 2024. The notice states the securities to be sold were acquired upon the vesting of restricted stock units during the period from July 9, 2024 through January 14, 2025.
Candel Therapeutics, Inc. (CADL) reported that director Martine Zimmermann received a grant of stock options covering 64,000 shares of Common Stock on September 8, 2026. The options have an exercise price of $12.60 per share and expire on September 8, 2036. The award vests in thirty-six equal monthly installments, subject to her continued service, and represents her direct beneficial ownership of these derivative securities. No Rule 10b5-1 trading plan is reported for this grant.
Candel Therapeutics, Inc. (CADL) reported that Martine Zimmermann, a director of the company, filed an initial statement of beneficial ownership on Form 3. The filing lists no equity holdings or reportable transactions in Candel Therapeutics securities at this time.
Candel Therapeutics, Inc. (CADL) expanded its Board of Directors from ten to eleven members and appointed Martine Zimmermann, Pharm.D. as a Class III independent director, effective September 8, 2026, with a term expiring at the 2027 annual stockholders’ meeting. Her compensation includes an option to purchase 64,000 shares of common stock, vesting monthly over three years, and a $40,000 annual cash retainer, paid quarterly and pro rated for service. Candel highlights Dr. Zimmermann’s more than 30 years of global regulatory and quality experience as it prepares for a planned Biologics License Application (BLA) submission for aglatimagene besadenovec in the fourth quarter of 2026 and potential commercial readiness. The company also reiterates that more than 1,000 patients have received aglatimagene in clinical trials and summarizes multiple FDA designations, including Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy, for its lead programs.
Candel Therapeutics, Inc. (CADL) furnished an investor presentation outlining clinical, commercial and financial updates across its oncology pipeline. Lead asset aglatimagene besadenovec (CAN-2409) achieved the primary endpoint in a randomized phase 3 trial in intermediate- to high-risk localized prostate cancer, delivering a 30% reduction in risk of disease-free survival events versus placebo plus standard of care (hazard ratio 0.70; P=0.0155) in 745 patients and a 38% reduction in prostate cancer-specific disease-free survival events (hazard ratio 0.62; P=0.0046).
The presentation reports supportive secondary outcomes, including higher pathological complete response rates on 2‑year biopsies (80% vs 63%) and more patients reaching PSA nadir <0.2 ng/mL (67.1% vs 58.6%). In PD‑1–refractory non-small cell lung cancer, phase 2a aglatimagene data show median overall survival up to 25.4 months, compared with historical chemotherapy benchmarks cited in the deck. Second program linoserpaturev (CAN‑3110) in recurrent high‑grade glioma shows median overall survival of about 11–12 months in early studies, versus historical 6–9 months referenced.
Financially, Candel highlights a term loan facility of up to $130 million, a $100 million royalty funding agreement contingent on prostate cancer approval, and $201.6 million of cash and cash equivalents as of June 30, 2026, which it states is expected to fund operations into the first quarter of 2028. The company also notes ongoing pre-commercialization efforts for a potential U.S. launch of aglatimagene in prostate cancer and states that a BLA filing is expected in the fourth quarter of 2026.
Candel Therapeutics, Inc. (CADL) reported that Chief Technology Officer Tyagarajan Seshu sold 7,000 shares of common stock at $12.00 per share on 2026-08-17 in an open-market or private transaction. Following this sale, Seshu directly held 76,865 shares of Candel Therapeutics common stock. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on 3/16/2026.
CADL reporting person Seshu P. Tyagarajan filed to sell 7,000 shares of common stock through Morgan Stanley Smith Barney LLC, with the shares listed on NASDAQ. The shares relate to Restricted Stock Units granted on 01/07/2025 and are associated with Rule 10b5-1 sales dated 06/29/2026, with disclosed transaction values of $82,040.00 and $70,151.20.
Candel Therapeutics, Inc. reported substantially higher operating investment and losses for the three and six months ended June 30, 2026, while significantly strengthening its balance sheet. Total assets were $208.1 million, driven largely by cash and cash equivalents of $201.6 million, up from $119.7 million at year-end after a $100 million follow-on equity offering (net proceeds $93.5 million) and $24.2 million raised through at-the-market sales.
Operating expenses more than doubled year over year, with research and development of $19.8 million and general and administrative of $6.9 million in the quarter, leading to a Q2 2026 net loss of $38.9 million versus a $4.8 million loss a year earlier. For the first half, the company posted a net loss of $47.8 million versus $2.6 million of net income in 2025, reflecting increased clinical spend, higher commercial readiness costs, and a non-cash loss from remeasuring warrant liabilities. Net cash used in operating activities was $35.2 million in the first half. Candel also has a $50 million Trinity Capital term loan outstanding and believes its current resources will fund planned operations for at least 12 months. The company continues to advance aglatimagene and linoserpaturev through clinical trials, supported by an RTW royalty-based funding agreement contingent on future FDA approval of aglatimagene.
Candel Therapeutics reported second-quarter 2026 results and progress across its oncology pipeline. The company is planning a Biologics License Application in Q4 2026 for aglatimagene besadenovec in localized, intermediate- to high-risk prostate cancer, supported by pivotal phase 3 data published in The Lancet Oncology showing improved disease-free survival versus radiotherapy alone. A global pivotal phase 3 AURORA trial in metastatic non-squamous NSCLC has opened enrollment, and development planning continues for linoserpaturev in recurrent glioblastoma.
Research and development expenses rose to $19.8 million from $7.0 million, and general and administrative expenses to $6.9 million from $4.2 million, driving a wider net loss of $38.9 million versus $4.8 million a year earlier, largely due to warrant liability remeasurement. Cash and cash equivalents were $201.6 million at June 30, 2026, up from $119.7 million at December 31, 2025, which the company expects will fund its operating plan into Q1 2028, including preparations for a potential U.S. commercial launch of aglatimagene in 2027 if approved.